ACTA1 and head and neck squamous cell carcinoma: In each patient cohort, moderate/high levels of stromal α-SMA identified patients with statistically significantly increased disease-specific mortality (all log-rank P ≤ .01; HNSCC [oral]: HR =  3.13, 95% CI =  2.07 to 4.74, P < .001; HNSCC [oropharyngeal]: HR = 1.69 , 95% CI = 1.11 to 2.57, P = .01; CRC: HR =  7.25, 95% CI =  1.68 to 31.30, P = .008) (Figure 1A;, Supplementary Figure 1A, available online).